Aspire BioPharma, Inc. Market Cap ($10.24 Million)
Market Cap & Net Worth: Aspire BioPharma, Inc. (ASBP)
Aspire BioPharma, Inc. market cap. Aspire BioPharma, Inc. (NASDAQ:ASBP) has a market capitalization of $10.24 Million ($10.24 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26867 globally and #5588 in its home market, demonstrating a -17.05% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aspire BioPharma, Inc.'s stock price $7.30 by its total outstanding shares 1402557 (1.40 Million). Also see ASBP cash generation efficiency for how efficiently the company converts equity into cash flow.
Aspire BioPharma, Inc. Market Cap History (2025–2026)
Aspire BioPharma, Inc. market cap history from 2025 to 2026. Data shows growth from $185.00K to $10.24 Million (85.50% CAGR). Check Aspire BioPharma, Inc. (ASBP) share price today for real-time trading data and today's change.
Aspire BioPharma, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aspire BioPharma, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Aspire BioPharma, Inc. annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
29.83x
Aspire BioPharma, Inc.'s market cap is 29.83 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $185.00K | $6.20K | -$24.48 Million | 29.83x | N/A |
Competitor Companies of ASBP by Market Capitalization
Companies near Aspire BioPharma, Inc. in the global market cap rankings as of November 4, 2026. Also see ASBP total assets for a full breakdown of the balance sheet.
Key companies related to Aspire BioPharma, Inc. by market ranking:
- O’Reilly Automotive Inc (NASDAQ:ORLY): Ranked #385 globally with a market cap of $73.77 Billion USD.
- AutoZone Inc (NYSE:AZO): Ranked #567 globally with a market cap of $47.07 Billion USD.
- DENSO CORP. ADR 4 (F:DNOA): Ranked #942 globally with a market cap of $28.19 Billion USD ( €24.12 Billion EUR).
- SUMITOMO EL.IND.ADR (F:SMO1): Ranked #1019 globally with a market cap of $25.89 Billion USD ( €22.15 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #385 | O’Reilly Automotive Inc | NASDAQ:ORLY | $73.77 Billion | $90.70 |
| #567 | AutoZone Inc | NYSE:AZO | $47.07 Billion | $3253.01 |
| #942 | DENSO CORP. ADR 4 | F:DNOA | $28.19 Billion | €9.95 |
| #1019 | SUMITOMO EL.IND.ADR | F:SMO1 | $25.89 Billion | €54.00 |
Market Capitalization of Aspire BioPharma, Inc. (2025–2026)
Market capitalization of Aspire BioPharma, Inc. from 2025 to today. Between 2025 and today, Aspire BioPharma, Inc.'s market cap moved from $185.00K to $ 10.24 Million, with a yearly change of 85.50%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $10.24 Million | +5434.50% |
| 2025 | $185.00K | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Aspire BioPharma, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.24 Million USD |
| MoneyControl | $10.24 Million USD |
| MarketWatch | $10.24 Million USD |
| marketcap.company | $10.24 Million USD |
| Reuters | $10.24 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Aspire BioPharma, Inc.
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually admi… Read more